Michigan Supreme Court sides with Nessel, overrules cases curtailing consumer protection law

The Michigan Supreme Court has ruled in favor of Attorney General Nessel, effectively overruling previous legal cases that had curtailed the application of consumer protection law within the state. According to reports from the Michigan Advance and The Detroit News, this judicial decision removes previous barriers that had blocked investigations into specific business practices. A primary outcome of this ruling is the immediate restoration of the state's ability to conduct probes into insulin pricing, as highlighted by WOODTV.com and WLNS 6 News. The court's action effectively reverses decisions that had previously shielded certain entities from these regulatory investigations. Coverage from Crain's Grand Rapids Business emphasizes that the ruling now opens a wide array of industries to consumer protection lawsuits, suggesting a significant shift in the legal landscape for Michigan businesses. This development has been met with varied reactions across different sectors.

For instance, the NFIB has stated that the Michigan Supreme Court ruling undermines existing protections for small businesses. Conversely, Senator Singh, as reported by Michigan Senate Democrats, has uplifted the ruling as a necessary step to restore consumer protection across the state. Attorney General Nessel also issued a formal statement following the court's decision to reverse the previous consumer protection decisions. To understand the current context, it is necessary to note that prior cases had actively blocked investigations, particularly those focused on the pricing of insulin. These earlier rulings had limited the scope of consumer protection laws, creating a legal environment where certain pricing structures and industry practices were shielded from state oversight. By siding with Nessel, the Supreme Court has dismantled these specific limitations, thereby re-establishing the authority of the Attorney General's office to investigate potentially unfair or deceptive pricing practices that affect the general public.

Looking forward, the immediate focus will be on the execution of drug-pricing probes, as the path has now been cleared for these investigations to proceed. Stakeholders are monitoring how the wide array of industries mentioned by Crain's Grand Rapids Business will be impacted by the increased vulnerability to consumer protection lawsuits. Because the NFIB has raised concerns regarding small business protections, the application of this ruling across different business sizes may become a point of contention. The state will now likely move forward with the insulin pricing investigations that were previously stalled by the overturned cases.